Approval · Notice of Compliance 2417 · 2001
MESASAL: Notice of Compliance 2417
Issued August 24, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2417
- Date
- August 24, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Lower gastrointestinal anti-inflammatory
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MESASAL | 01914030 | Cancelled Post Market |
| MESASAL | 02028751 | — |
| MESASAL | 02028778 | — |
Medicinal ingredients
- MESALAZINE 500 MG per TAB
- MESALAZINE 250 MG per SUP
- MESALAZINE 500 MG per SUP